Orbsen Therapeutics

11/10/2019

https://www.siliconrepublic.com/start-ups/nui-galway-spin-outs

From medtech and medical device companies to energy and environment start-ups we've rounded up 10 of Galway's university spin-outs.

20/06/2019

28/01/2019

If you are or know someone who would be interested in joining a growing clinical stage cell therapy company we have a position available in our GMP manufacturing team in the UK. View the link below or email [email protected] for further information.
https://www.nature.com/naturecareers/job?id=673011

05/10/2018

GALWAY, Ireland, Oct. 03, 2018 /PRNewswire-PRWeb/ -- Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercializatio...

16/05/2018

Fantastic presentation by our Orbsen-BrainMatTrain PhD student Olivia Ng in summer research meeting, Glasgow!
Well done Olivia!!

13/03/2018

Orbsen Therapeutics UK is delighted to be part of this consortium !!

A recently formed health consortium, jointly led by the National Institute for Health Research Birmingham Biomedical Research Centre (NIHR BRC) and NHS Wales, has been awarded £7 million by Innovate UK to ensure more patients benefit from a new generation of breakthrough therapies.

13/03/2018

Equity investment and binding letter of intent outlines expansion of collaboration, including exclusive option for development and commercialization

27/02/2018

‪Day 2 at the bioanalytical assay dev & validation course! ‬

10/01/2018

Although the promise of stem cell therapy didn't fulfill some of its early promises, two small companies are quietly working to change that.

10/01/2018

Welcoming new researchers to AUTOSTEM Posted on 13th December 2017 by autostem_admin Four AUTOSTEM partners have added new staff members. We welcom...

05/01/2018

https://www.genengnews.com/gen-news-highlights/takeda-to-acquire-tigenix-for-520m/81255343/?utm_medium=newsletter&utm_source=gen+daily+news+highlights&utm_content=02&utm_campaign=gen+daily+news+highlights_20180105

Deal designed to strengthen Takeda’s late-stage gastroenterology pipeline and presence in the U.S. specialty care market.